Orchestra BioMed Holdings (OBIO) Common Equity (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has 7 years of Common Equity data on file, last reported at $41.2 million in Q1 2026.

• On a quarterly basis, Common Equity rose 144.36% year-over-year to $41.2 million in Q1 2026; TTM through Mar 2026 was $41.2 million, a 144.36% increase from a year earlier, with the FY2025 full-year figure at $53.6 million, up 62.54% from the prior year.
• Common Equity for Q1 2026 stood at $41.2 million, down from $53.6 million in the prior quarter.
• Over the last five years, Common Equity for OBIO reached as high as $99.8 million in Q1 2023 and fell as low as $78000.0 in Q1 2022.
• Historically, Common Equity has averaged $50.4 million across 5 years, with a median of $52.5 million in 2022.
• Across the five-year window, Common Equity jumped 127787.18% in 2023 and slumped 99.33% in 2025, its largest moves.
• Year by year, Common Equity stood at $52.5 million in 2022, then advanced by 29.52% to $68.0 million in 2023, then plunged by 51.56% to $33.0 million in 2024, then soared by 62.54% to $53.6 million in 2025, then declined by 23.11% to $41.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $41.2 million in Q1 2026, $53.6 million in Q4 2025, and $43.7 million in Q3 2025.